Editas Medicine Inc (EDIT) Gets a Buy Rating from Chardan Capital

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Editas Medicine Inc (EDIT – Research Report), with a price target of $55. The company’s shares closed More »

H.C. Wainwright Reaffirms Their Buy Rating on Cytokinetics Inc (CYTK)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Cytokinetics Inc (CYTK – Research Report), with a price target of $21. The company’s shares closed on More »